Evidence Hub

Takotsubo syndrome a rare entity in patients with COVID-19: An updated review of case-reports and case-series

Hardik D. Desai, Dhigishaba M. Jadeja, K. Sharma

International Journal of Cardiology: Heart & Vasculature, 2020

14,043,176 participants · 26 citations

Abstract

https://doi.org/10.1016/j.ijcha.2020.100604 2352-9067/ 2020 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativ Since December-2019 coronavirus disease 2019 (COVID-19) has swept the world. As of 19th July, it has affected 14,043,176 people and 5,97,583 death with CFR of 4.25 globally as per WHO Situation Report. COVID-19 infection has myriad cardiac manifestation with preceding coronavirus outbreaks such as SARS and MERS [1]. Various Cardiovascular complication have been reported in previous published studies and can manifest as ACS, stress cardiomyopathy, myocarditis, myopericarditis, heart failure, arrhythmias, pericardial effusion, cardiac tamponade, thromboembolic complications, and cardiogenic shock amongst COVID-19 patients. [2]. It is hypothesized that virus causes cardiac injury via direct cytotoxic effects or via immune-mediated mechanisms. Current evidence suggests that Sars-Cov-2 binds to ACE-2 receptor present on various tissues like lung, kidney, heart, vascular endothelium and downregulates expression of this enzymes, producing enhanced vasoconstriction and deleterious effects of unopposed reticuloendothelial system [1]. Takotsubo syndrome (TTS) is a rare cardiac complication which might be misdiagnosed in high risk cardiac patients of COVID-19. However, there is limited data available on TTS in COVID-19. We aimed to perform a review of the published case reports and series and pertinent…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free